Regorafenib inhibits EphA2 phosphorylation damages the liver via ERK/MDM2/p53 axis
Hao Yan(Zhejiang University), Peihua Luo(Zhejiang University)
Cited by 0
Related Papers
A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
|Frontiers in Pharmacology|2020|80
Formononetin protects against cisplatin‑induced acute kidney injury through activation of the PPARα/Nrf2/HO‑1/NQO1 pathway
|International Journal of Molecular Medicine|2020|65
Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion
|Autophagy|2023|56
s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand–foot skin reaction that can be reversed by nicotinamide
|Cell Research|2020|44
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis
|Nature Communications|2023|39